Opus GeneticsIRD +0.94%24 FCF Margin % is -590.03% as of Mar. 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 960 Biotechnology companies, Opus Genetics ranks worse than 65.94% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Opus Genetics's Free Cash Flow for the
three
months ended in Mar. 2026 was $-12.73 Mil. Opus Genetics's Revenue for the
three
months ended in Mar. 2026 was $2.16 Mil. Therefore, Opus Genetics's FCF Margin % for the quarter that ended in Mar. 2026 was -590.03%.
The historical rank and industry rank for Opus Genetics's FCF Margin % or its related term are showing as below:
IRD'
s FCF Margin % Range Over the Past 10 Years
Min: -3288.62 Med: -232.68 Max: 35.92
Current: -325.34
During the past 7 years, the highest FCF Margin % of Opus Genetics was 35.92%. The lowest was -3288.62%. And the median was -232.68%.
IRD's FCF Margin % is ranked worse than 65.94% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs IRD: -325.34
Opus Genetics FCF Margin % Related Terms
Opus Genetics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Opus Genetics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Opus Genetics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Opus Genetics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (IRD) has a FCF Margin % of -590.03% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Opus Genetics and its competitors. According to the industry distribution chart, Opus Genetics ranks #633 out of 960 companies in the Biotechnology industry, placing it in the top 65.9%.
Is Opus Genetics' FCF Margin % too high?
Opus Genetics' current FCF Margin % is -590.03%. Based on the distribution chart, Opus Genetics ranks #633 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' FCF Margin % compare to IFRX and RGNX?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #633 out of 960 companies for FCF Margin %. This places Opus Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Opus Genetics and its competitors. Opus Genetics's current FCF Margin % is -590.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $3.74 — trading 910.8% above its estimated fair value. The current FCF Margin % is -590.03%. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Opus Genetics (IRD), the current FCF Margin % is -590.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $3.74 is trading 910.8% above its estimated GF Value™ of $0.37.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
FCF Margin %: -590.03%
GF Value™: $0.37 vs. price of $3.74 (910.8% above fair value)
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score
Get the complete analysis for IRD
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 
